Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized platform immunotherapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immune suppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. Our lead candidate, SV-102 for mCRPC, is in Phase 2 trials. Syncromune is headquartered in Fort Lauderdale, FL, and West Des Moines, IA, USA. For more information, please visit www.syncromune.com.
At Syncromune, we care deeply and are united by our patient-centric approach that drives every endeavor in our relentless pursuit to cure cancer. Guided by unwavering ethical principles, we hold ourselves to the highest standards, conducting ourselves with integrity and relying on the power of unique perspectives through diversity and inclusion to cultivate a workplace that enables our employees to thrive. Together we challenge the ordinary with extraordinary, daring solutions and let fun provide balance to the serious work we do.